Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma

NCT01634113 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

102

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: tiotropium-bromide
DRUG: tiotropium-bromide
DRUG: placebo

Sponsor

Boehringer Ingelheim

Collaborators

[object Object]